Taletrectinib for ROS1-positive NSCLC
Taletrectinib is currently being evaluated in Phase 2 clinical trials for TKI-naïve and TKI-pretreated ROS1-positive NSCLC.
| Trial Title | Trial Number | Stage | Status | KEY Publication |
|---|---|---|---|---|
|
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II) |
Phase 2, Global (US, Japan, Korea, Europe, Canada, and China) |
Recruiting |
ESMO 2023, Interim Efficacy and Safety Results as of July 12, 2023 |
|
|
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene (TRUST-1) |
Phase 2, China |
Recruiting |
ELCC 2023, Updated Efficacy and Safety Results as of Dec 31, 2022 |
|
|
Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors |
Phase 1, Japan |
Completed |
JTO 2021, pooled analysis of US and Japan Phase 1 studies |
|
|
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b |
Phase 1, US |
Completed |
JTO 2021, pooled analysis of US and Japan Phase 1 studies |
SAFUSIDENIB FOR IDH1-MUTANT SOLID TUMORS
Safusidenib is being evaluated in a Phase 2 clinical trial for IDH1-mutant glioma.
| Trial Title | Trial Number | Stage | Status | KEY Publication |
|---|---|---|---|---|
|
Safusidenib Phase 2 Study in IDH1 Mutant Glioma |
Phase 2, Global (currently recruiting in US, global expansion planned) |
Recruiting |
Patient Access to Investigational Medicines
Contact Us
For questions about ongoing clinical trials, please contact trials@anhearttherapeutics.com.
